News

Therapeutic Solutions International has filed a patent for the use of a type of immune cell, called a dendritic cell, to potentially treat Parkinson’s disease. The patent application includes data, obtained in an animal model, showing that dendritic cells obtained from umbilical cord blood have the potential to…

People with mild Parkinson’s disease sleep less, are less active, and show more sedentary behavior than their healthy peers, a small study showed. Poorer sleep also significantly associated with more sedentary time in both populations. While further research is needed to confirm these early findings, they suggest that screening for…

Parkinson’s disease brain cells form abnormal networks that might predispose the cells toward damage, according to new research done using cells in laboratory conditions. “These discoveries open the door to early diagnosis, which would allow us to carry out a premature intervention that would slow down neuronal death, and…

People with Parkinson’s disease who use voice-assisted technologies (VATs) — software programs that respond to voice commands, like Amazon’s Alexa or Apple’s Siri — may find that they help to improve their speech by prodding them to practice speaking more clearly, a study based on an online patient survey…

Nb10 and TiNb9, two nanoparticles of a particular chemical element, effectively reduce the formation of toxic amyloid fibrils — a hallmark of Parkinson’s and Alzheimer’s diseases, a lab dish study showed. Particularly, these nanoparticles suppressed the assembly of toxic clumps of S100A9, a pro-inflammatory molecule that is central to…

Alector and GlaxoSmithKline (GSK) will collaborate in developing and commercializing two therapies aimed at treating an uncommon type of dementia that can cause problems with behavior and language. Both investigational therapies — AL001 and AL101 — can be used across a range of neurodegenerative disorders, including Parkinson’s,…

Impulse control disorders (ICDs) among people with Parkinson’s disease were significantly more common and more severe after a COVID-19-related lockdown than before the pandemic, according to a small study in Spain. Also, patients who developed ICDs in the post-lockdown period were younger, developed Parkinson’s at a younger age, or had more…

A new human-derived model of the blood-brain barrier (BBB) — a highly selective and protective membrane whose dysfunction is linked to Parkinson’s disease — enables researchers to monitor in detail cellular events upon stress, inflammation, and therapy administration, a study shows. This model allowed the assessment of the protective effects of…

The Michael J. Fox Foundation (MJFF) is funding a variety of Parkinson’s disease studies, ranging from projects focused on environmental risk factors and exercise to therapeutic gene targets and new tests. A total of 36 grants were awarded, amounting to $6.3 million. Several of the MJFF-funded projects are…

Treatment with ISC-hpNSC, an investigational stem cell therapy for Parkinson’s disease, was safe and well-tolerated over at least two years in an early clinical trial in 12 patients. Results from the small trial, which treated patients at low, medium and high doses, also indicate that the therapy eased Parkinson’s-related symptoms…